Oxford Biomedica, a leading quality and innovation-led cell and gene therapy Contract Development Manufacturing Organization, and Institut Mérieux announce that they have entered into exclusive negotiations concerning Oxford Biomedica’s proposed acquisition of ABL Europe.

Click here to read the full press release.